**Amendment #1**

**"Clinical Research Products Management Center"**

+------------------------+---------------------------------------------+
| **Amendment No.**      | One (1)                                     |
|                        |                                             |
| **Amendment Issue      | May 2, 2005                                 |
| Date:**                |                                             |
+------------------------+---------------------------------------------+
| **Proposal Due         | **June 7, 2005, at 4:00 P.M., EST**         |
| Date/Time:**           | **[(CHANGED)]{.mark}**                      |
+------------------------+---------------------------------------------+
| **Issued By:**         | Barbara A. Shadrick                         |
|                        |                                             |
|                        | Contracting Officer                         |
|                        |                                             |
|                        | RRCB/CMP/DEA/NIAID/NIH/DHHS                 |
|                        |                                             |
|                        | 6700-B Rockledge Drive, Room 3214,          |
|                        |                                             |
|                        | Bethesda, Maryland 20892-7612               |
+------------------------+---------------------------------------------+
| **Points of Contact:** | <dreeves@niaid.nih.gov>                     |
|                        |                                             |
|                        | Dominic Reeves, Contract Specialist         |
|                        |                                             |
|                        | Phone: 301-451-3683                         |
|                        |                                             |
|                        | **Please also cc:**                         |
|                        |                                             |
|                        | <dlisle@niaid.nih.gov>                      |
|                        |                                             |
|                        | David Lisle, Contract Specialist            |
|                        |                                             |
|                        | Phone: 301-451-2617                         |
+------------------------+---------------------------------------------+

**Offerors must acknowledge receipt of this [Amendment #1,]{.underline}
on each copy of the proposal submitted. Failure to receive your
acknowledgment of this Amendment may result in the rejection of your
proposal.**

***[THE FACE PAGE OF THE REQUEST FOR PROPOSAL, Box 4, DUE DATE, is
amended as follows]{.underline}:***

**[The date specified for receipt of proposals is revised from May 23,
2005 to June 7, 2005, to correct an error in Box 4 of the Face Page of
the RFP:]{.mark}**

> 4: Due Date: June 7, 2005
>
> Time: 4:00 p.m., EST

***[THE STATEMENT OF WORK IS REVISED AS FOLLOWS]{.underline}:***

### *PAGE 5, STATEMENT OF WORK, paragraph 1.d, is amended to read as follows:*

1\. INITIAL TRANSITION (CONTRACT START-UP)

d.  In the event of a transition to a successor contractor, the current
    CRPMC will provide to the new contractor the existing Oracle® data
    base management system of the CRPMC, the Clinical Products Inventory
    Management System (CPIMS), containing information on inventory, and
    necessary documentation of the activities of the CRPMC. A major
    component of the system is the module to track individual
    investigators' product requests. Other modules support production of
    standard reports, such as receiving and shipping. More specialized
    reports including inventory by product and by study protocol, list
    of clinical research sites and pharmacists of record will also be
    made available. The CRPMC computer files will be transferred.

### 

### *PAGE 7, STATEMENT OF WORK, paragraph 2 d.7), is amended to read as follows:*

**2. PHARMACEUTICAL SERVICES**

> **d. Study Products**
>
> **7)** Obtain and provide to DAIDS PAB, current Average Wholesale
> Prices for study products using [Drug Topics® Red Book®]{.underline}
> or "equal" on CD-ROM to provide to protocol teams for budget
> estimating purposes. The equivalent item will:

-   provide nationally recognized average wholesale prices (AWPs)

-   provide NDC numbers for all FDA-approved drugs

-   provide complete package information including dosage form, route of
    administration, strength, and size for all FDA-approved drugs

-   be updated a minimum of four times yearly

-   be available through electronic media, for example, website, cd-rom,
    etc.

### *PAGE 14, STATEMENT OF WORK, paragraph 10.f, is amended to read as follows:*

**10. SECURITY AND SAFETY OF STUDY PRODUCTS**

> **f.** Provide an Inergen® or equivalent clean agent fire suppression
> system that is environmentally acceptable and leaves no residues. The
> equivalent fire suppression will:

-   be non-corrosive

-   not support combustion

-   not react chemically with most substances

-   not be a water based system

-   not impact the environment

-   not deplete the ozone layer

-   protect study products permitting use even after discharge of the
    system

**\[THE REMAINDER OF THE STATEMENT OF WORK IS UNCHANGED.\]**